Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma

Kelsey Musselman; Shannon Glynn; Juan Miguel Mosquera; Olivier Elemento; Andrea Sboner; Himisha Beltran; Kevin Holcomb

doi:10.1016/j.gore.2019.01.013

Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma

Kelsey Musselman, Shannon Glynn, Juan Miguel Mosquera, Olivier Elemento, Andrea Sboner, Himisha Beltran, Kevin Holcomb

Research output: Contribution to journal › Article › peer-review

Abstract

Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/neu via fluorescence in situ hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response.

Original language	English (US)
Pages (from-to)	54-57
Number of pages	4
Journal	Gynecologic Oncology Reports
Volume	28
DOIs	https://doi.org/10.1016/j.gore.2019.01.013
State	Published - May 2019
Externally published	Yes

Keywords

Genetic sequencing
HER2/neu
Precision medicine
Trastuzumab
Uterine papillary serous carcinoma
Uterine serous adenocarcinoma, uterine serous carcinoma

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/j.gore.2019.01.013

Cite this

@article{1c787c26ce494f48a9765ce88a168076,

title = "Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma",

abstract = "Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/neu via fluorescence in situ hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response.",

keywords = "Genetic sequencing, HER2/neu, Precision medicine, Trastuzumab, Uterine papillary serous carcinoma, Uterine serous adenocarcinoma, uterine serous carcinoma",

author = "Kelsey Musselman and Shannon Glynn and Mosquera, {Juan Miguel} and Olivier Elemento and Andrea Sboner and Himisha Beltran and Kevin Holcomb",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = may,

doi = "10.1016/j.gore.2019.01.013",

language = "English (US)",

volume = "28",

pages = "54--57",

journal = "Gynecologic Oncology Reports",

issn = "2211-338X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma

AU - Musselman, Kelsey

AU - Glynn, Shannon

AU - Mosquera, Juan Miguel

AU - Elemento, Olivier

AU - Sboner, Andrea

AU - Beltran, Himisha

AU - Holcomb, Kevin

PY - 2019/5

Y1 - 2019/5

N2 - Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/neu via fluorescence in situ hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response.

AB - Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/neu via fluorescence in situ hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response.

KW - Genetic sequencing

KW - HER2/neu

KW - Precision medicine

KW - Trastuzumab

KW - Uterine papillary serous carcinoma

KW - Uterine serous adenocarcinoma, uterine serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85062404908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062404908&partnerID=8YFLogxK

U2 - 10.1016/j.gore.2019.01.013

DO - 10.1016/j.gore.2019.01.013

M3 - Article

AN - SCOPUS:85062404908

SN - 2211-338X

VL - 28

SP - 54

EP - 57

JO - Gynecologic Oncology Reports

JF - Gynecologic Oncology Reports

ER -

Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this